Cristian Massacesi, M.D., Appointed to Replay Board of Directors
Retrieved on:
Thursday, May 25, 2023
HSV, Medical jurisprudence, Abstract, DNA, Drug development, Marche Polytechnic University, Writing, Lung cancer, Royal Marsden Hospital, Head, Research, KKR, Immunotherapy, AstraZeneca, European Institute, European Institute of Oncology, Novartis, Genome, The Royal Marsden NHS Foundation Trust, AZN, School, Our Boarding House, Alexion, Biology, Entrepreneurship, Growth, Knowledge, Pfizer, Breast cancer, Bone marrow, Pharmaceutical industry, Management, Nursing, Oncology, Replay, Radiation therapy
Dr. Massacesi is a leading expert in medical oncology, with over 20 years of research and drug development experience in the pharmaceutical industry.
Key Points:
- Dr. Massacesi is a leading expert in medical oncology, with over 20 years of research and drug development experience in the pharmaceutical industry.
- Prior to that, as Global Clinical Program Head, he led the company’s PI3K-inhibitors portfolio through clinical development, including registrational studies and submissions.
- Adrian Woolfson, Executive Chairman, President, and Co-founder of Replay, commented: “Cristian has an exceptional reputation within the life sciences community and his extensive experience and expertise in leading oncology clinical development programs is a significant addition to Replay’s board.
- I am excited to be joining as a board member and to be supporting such a strong and dynamic team.